Cargando…

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction

AIMS: In heart failure with preserved ejection fraction (HFpEF), regional heterogeneity of clinical phenotypes is increasingly recognized, with coronary microvascular dysfunction (CMD) potentially being a common shared feature. We sought to determine the regional differences in clinical characterist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erhardsson, Mikael, Ljung Faxén, Ulrika, Venkateshvaran, Ashwin, Svedlund, Sara, Saraste, Antti, Lagerström Fermer, Maria, Gan, Li‐Ming, Shah, Sanjiv J., Tromp, Jasper, SP Lam, Carolyn, Lund, Lars H., Hage, Camilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682847/ https://www.ncbi.nlm.nih.gov/pubmed/37920127 http://dx.doi.org/10.1002/ehf2.14569

Ejemplares similares

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study
por: Patel, Ravi B., et al.
Publicado: (2021)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Left atrial reservoir strain improves diagnostic accuracy of the 2016 ASE/EACVI diastolic algorithm in patients with preserved left ventricular ejection fraction: insights from the KARUM haemodynamic database( )
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
por: Anttila, Vesa, et al.
Publicado: (2020)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
por: Shahim, Angiza, et al.
Publicado: (2023)

Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study
por: Shahim, Angiza, et al.
Publicado: (2021)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Circulating neuregulin1‐β in heart failure with preserved and reduced left ventricular ejection fraction
por: Hage, Camilla, et al.
Publicado: (2020)

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
por: Prescott, Eva, et al.
Publicado: (2020)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
por: Hage, Camilla, et al.
Publicado: (2020)

Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization
por: Lund, Lars H, et al.
Publicado: (2023)

Cardiogenic shock triggered by phaeochromocytoma crisis after an oral glucose tolerance test: a case report
por: Shahim, Bahira, et al.
Publicado: (2019)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report
por: Narang, Nikhil, et al.
Publicado: (2017)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study
por: Lundberg, Anders, et al.
Publicado: (2018)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Weerts, Jerremy, et al.
Publicado: (2022)

Extracellular vesicles in heart failure – A study in patients with heart failure with preserved ejection fraction or heart failure with reduced ejection fraction characteristics undergoing elective coronary artery bypass grafting
por: Matan, Dmitri, et al.
Publicado: (2022)

Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction
por: Sharma, Abhinav, et al.
Publicado: (2022)

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction
por: Giamouzis, Gregory, et al.
Publicado: (2016)

Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction
por: Sickinghe, Ariane A., et al.
Publicado: (2019)

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
por: Packer, Milton, et al.
Publicado: (2020)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Tay, Wan Ting, et al.
Publicado: (2021)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
por: Tromp, Jasper, et al.
Publicado: (2017)

The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction
por: Sandesara, Pratik B., et al.
Publicado: (2018)

Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
por: Mordi, Ify R., et al.
Publicado: (2020)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links?
por: Sinha, Aish, et al.
Publicado: (2023)

Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure
por: Venkateshvaran, Ashwin, et al.
Publicado: (2019)

PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
por: Haraldsson, Inger, et al.
Publicado: (2019)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Progression of coronary microvascular dysfunction to heart failure with preserved ejection fraction: a case report
por: Joung, Sandy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2mk14lko45ov5doi0u9pcde4ma